






Government of **Western Australia**
South Metropolitan Health Service



Research Report **2024**



Contents

Foreword	5	Data	30
From the SMHS A/Chief Executive	5	Research activity overview	31
Acknowledgements	6	Spotlight: data in research	32
Executive summary	7		
Community	8	Support	38
Enabling consumer involvement in research	9	Research Support and Development Unit	39
SMHS Research Steering Committee		Research Business Support team	40
Consumer Representative	10	Research Integrity	40
Spotlight: community in research	11	Improving access to publication funding support	41
		SMHS Human Research Ethics Committee (HREC)	41
Collaboration	18	Waiver of consent	43
Forging connections	19	Research Screener	45
Facility upgrades improving research outcomes	19	Research projects	46
Spotlight: collaboration in research	20		
Culture	24		
New Clinical Lead – Research	25		
The Nursing and Midwifery Research Unit	25		
The Allied Health Research Unit	26		
Seventh annual SMHS Research Showcase	27		
Researcher of the Year	28		
Spotlight: research culture	29		
Striving to improve cardiac catheterisation protocols	29		



*Neil Doverty
A/Chief Executive
South Metropolitan Health Service*

'Research with purpose – working in partnership
with SMHS communities and beyond to deliver
excellence in health and wellbeing.'

Foreword

The South Metropolitan Health Service (SMHS) Research Report 2024 highlights research activity undertaken across all SMHS hospitals and community-based services in the 2024 calendar year.

From the SMHS A/Chief Executive

It is a pleasure to share with you our ninth annual SMHS Research Report.

This report shines a light on the impressive volume of diverse research activity conducted across SMHS sites during 2024 and associated research translation activities occurring via publications. Importantly, it also details the continuing growth of our research culture, capacity and capability as we build our collaborative research strategy.

The report aligns with the five pillars of change within the [SMHS Research Strategy 2023–2033](#) – **Community, Collaboration, Culture, Data and Support**. These pillars represent our commitment to growing our research environment and achieving our research vision of, **‘Research with purpose – working in partnership with SMHS communities and beyond to deliver excellence in health and wellbeing.’**

Once again, our seventh annual SMHS Research Showcase enabled us to celebrate and showcase our researchers’ work and accomplishments. We thank the many presenters and judges for sharing their time and expertise to support the showcase events, and congratulate **Parmida Ghorbanian, PhD student Cardiology**, winner of the three-minute project competition.

Neil Doverly
A/Chief Executive
South Metropolitan Health Service

Acknowledgements

This report was developed with contributions from:

- researchers from multiple departments as detailed within this report
- SMHS Research Steering Committee
- SMHS/East Metropolitan Health Service Library team
- SMHS Corporate Communications team
- SMHS Research, Support and Development Unit team
- SMHS Research Business Support team.

Executive summary

The SMHS Board has outlined research as a key enabler to deliver on its strategic priority of **Excellence in the delivery of safe, high quality clinical care.**¹

Research is also recognised as a pivotal enabler of the other four SMHS strategic priorities:

- Provide a great patient experience.
- Engage, develop and provide opportunities for our workforce.
- Strengthen relationships with our community and partners.
- Achieve a productive and innovative organisation which is financially and environmentally sustainable.

This report captures research activity that occurred in SMHS during the 2024 calendar year.

While most research was conducted at Fiona Stanley Hospital (FSH), a significant number of projects involved collaboration across SMHS sites including Fremantle Hospital (FH), Rockingham General Hospital (RGH) and community-based services. Two new SMHS sites were also initiated to conduct research this year – Peel Health Campus and Cockburn Health.

To conduct high quality research projects and clinical trials, SMHS researchers collaborated with:

- local, national and international researchers
- universities
- medical research institutes
- commercial sponsors.

SMHS also received and administered grant funding from multiple funding bodies.

High-level summary of our 2024 research activity

88	16	3	174	1,324
projects received SMHS Human Research Ethics Committee (HREC) approval	waivers of consent were granted by the SMHS HREC	<i>Guardianship and Administration Act 1990 (GAA)</i> pathway projects were approved	projects were approved to proceed at SMHS sites (via governance)	publications that have an affiliation noted with SMHS or a SMHS site were sourced.

¹ [South Metropolitan Health Service - Strategic Plan](#)



Community

SMHS is committed to building an innovative research culture which values, promotes and welcomes community engagement.

Enabling consumer involvement in research

In recent years, recognition of the genuine and meaningful value of consumer involvement in research has increased in Australia and internationally.

Consumers can be involved in all levels of research, from providing advice and feedback to co-designing and leading projects. Their involvement in research:

- enhances scientific and ethical standards
- improves research outcomes and translation
- encourages fresh and independent perspectives
- builds stronger communication with consumers and the community
- increases job satisfaction among researchers.

SMHS understands that high-quality research projects and outcomes are achieved when consumers and researchers work in true and genuine partnership.

In 2023, SMHS Director Research Melanie Wright initiated a project to develop and implement a framework for guiding consumer involvement in SMHS research.

The framework also aimed to:

- align with the *SMHS Research Strategy 2023–2033* and *SMHS Strategic Plan 2021–2025*
- support compliance with the *National Clinical Trials Governance Framework* and the National Health and Medical Research Council (NHMRC) *National Statement on Ethical Conduct in Human Research*.

To ensure genuine consumer involvement, Melanie enlisted FSFHG Consumer Advisory Council Chair, Jane Pearce, as project lead. Jane, supported by Melanie and SMHS Research Project Officer Isabella McGavock, formed the project working group. The group developed a project brief and conducted a literature review before designing a plan to engage both consumers and researchers in shaping the framework through a series of workshops.

Launched at an event on 27 November 2024, the *SMHS Consumer Involvement in Research Framework 2024* gives SMHS consumers a voice in research while supporting researchers to develop meaningful, relevant research which values these perspectives.

Consumer and researcher solutions outlined in the framework are already being implemented, including the SMHS Consumer Registry, the SMHS Consumer Bank Fund and a dedicated SMHS Research Consumer Advisory Group.

Photo: Front row: SMHS Board Member Ms Yvonne Parnell, SMHS Board Chair Adjunct Associate Professor Robyn Collins, Jane Pearce, Melanie Wright and Isabella McGavock

SMHS Research Steering Committee Consumer Representative

As a full member of the SMHS Research Steering Committee and its consumer representative, I provide a strong consumer voice to committee discussions and decision-making processes.

Ensuring consumer perspectives are included in SMHS research activities is essential, for ultimately these consumers represent the patients, families, loved ones and community members who benefit from our medical research and clinical trials outcomes.

A key aim as consumer representative is to foster excellence in consumer involvement in research across the health service. Fortunately, I have found the consumer voice is increasingly being heard across SMHS, with more researchers seeking opportunities for consumer involvement in their research activities.



Consumer Representative Jane Pearce

"There is a clear commitment by SMHS to make consumer involvement in research standard practice in the future, and strong evidence that consumer perspectives are already helping shape the research culture."

Spotlight: community in research

Supporting culturally and linguistically diverse patients

A [Future Health Research and Innovation \(FHRI\) Fund Scholarship](#) is enabling nurse researcher Sarah Rooney to focus on better supporting patients and carers from culturally and linguistically diverse (CALD) backgrounds.

Sarah's research seeks to explore the challenges faced by patients and carers from CALD communities who use the CARE call initiative to escalate care in hospital.

Employing a participatory approach, Sarah seeks to co-design an intervention strategy that effectively addresses these challenges and promotes an equitable, inclusive approach to patient safety.

To ensure comprehensive representation of the diverse Western Australia (WA) community, a multicultural advisory group was established. The group is an integral component of the research and is guiding the research design and implementation.



Prof Fenella Gill, Dr Eileen Boyle, Sarah Rooney and Katarina Barjaktarevic.

By working in true partnership with consumers, Sarah hopes the research findings and outcomes will translate into meaningful, practical benefits for the CALD community.

Gaining valuable insight from one simple question

The ‘What matters to you?’ initiative supports care in line with a patient’s personal preferences and values. It achieves this by encouraging meaningful conversations between patients, carers, families and healthcare staff.

While it has been integrated into healthcare frameworks internationally, it was unclear how extensively and successfully it had been used for patient care.

A review of 20 articles by FSH nursing researchers Carrie Janerka, Ashley-Rose Hooper, Belinda Sanders and Olivia Gallagher confirmed it as a simple and versatile tool for supporting person-centred care, with perceived benefits for consumers, users, community and organisations.

The research identified that it assisted:

- healthcare staff to better understand the needs of specific patient groups
- with individual care planning, supporting:
 - patient involvement and empowerment
 - patient-practitioner communication and therapeutic relationships
 - the integration of psychosocial care
- health service improvement on a macro level (national guidelines), meso level (models of care, service design), and micro level (care plans, bedside posters).

Consumers were involved in interpreting results of the scoping review, utilising the SMHS Consumer Bank.

What Matters to You

My name is: _____

My nurse is: _____

What matters to me is: _____

Today's plan:
(include any future appointments, consults) _____

Questions for my treating team: _____

Today's date is: _____ **My expected discharge date:** _____

What matters to you?
Interpreter
Eye
Ear

Dec 2023; V1.6

Image of WMTY board

Ronald hoping to benefit from FSH ACCELERATE peanut allergy trial

For Ronald, a lifelong peanut allergy restricted his ability to eat out, take protein powders to assist his gym work and even follow his dream of attending the defence force.

“Peanut exposure impacts my ability to breathe, so I have carried an EpiPen since I was a child and have to be really careful when I eat,” Ronald said.

But thanks to his participation in the FSH-led ‘ACCELERATE Peanut’ study trial, Ronald may be eligible to receive IGX001, an injectable, allergen-specific antibody medicine that targets peanut protein to provide protection against an allergic reaction.

The Phase 1 trial will assess if IGX001 can help ease allergic reactions that might happen after accidental peanut exposure for patients like Ronald. It will monitor the safety of IGX001, track how participants respond to it, and explore whether participants improve their tolerance to peanut protein exposure after receiving IGX001.

Lead investigator of the trial, FSH Consultant Clinical Immunologist Dr Michael O’Sullivan, said IGX001 marks a potentially major step forward in treating peanut allergies worldwide.

“An increasing number of people live with peanut allergy and its ever-present risk of potentially life-threatening allergic reactions that can impact their physical,

social, emotional and psychological wellbeing,” Dr O’Sullivan said.

“Additionally, most people with peanut allergy never outgrow it, so there is an urgent need for treatment options to provide protection against allergic reactions such as Ronald’s anaphylaxis.”

By using cutting edge research to re-engineer harmful IgE antibodies to IgG4 blocking antibodies that bind to allergens without causing reactions, Dr O’Sullivan said this approach offers the potential for a faster, more effective alternative to current therapies.

“This innovative approach to desensitisation could transform the management of patients with peanut allergy – it could dramatically reduce their risk of anaphylaxis and need for emergency treatment with adrenaline, in turn reducing food allergy anxiety and improving quality of life.”



FSH Consultant Clinical Immunologist Dr Michael O’Sullivan



"For any other advanced melanoma patients looking for treatment options, I recommend doing your research to see what's available. Don't give up – anything's possible."

David, patient

Advanced melanoma patients first in Australia to receive tailor-made cell therapy

Fiona Stanley Hospital became the first hospital in the country to deliver patient-specific anti-cancer cell therapy to patients with advanced melanoma. The novel investigational treatment is part of a new cell therapy research trial called TILVance-301.

Lead trial researcher and FSH Medical Oncologist Professor, Adnan Khattak, said current advanced melanoma immune modulating treatments were not patient specific.

“We are evaluating whether adding patient-specific cellular therapy derived from a patient’s own tumour tissue, in combination with the currently used immunotherapy, will have greater efficacy for advanced melanoma than immunotherapy alone,” Professor Khattak said.

“With patient-specific cellular therapy, part of the patient’s cancer is surgically removed and sent to a laboratory overseas. The patient’s tumour specific immune cells are then harvested and cultured to grow into immune cells designed to specifically target that individual patient’s tumour.

“The tailor-made treatment is then sent back to FSH where it is given to the patient by infusion on the ward.”

The novel therapy research aims to improve outcomes for patients with advanced melanoma, like 57-year-old David Braund.

Just the second WA patient to receive the treatment, the Bedforddale air conditioning business owner first noticed a lump on the side of his head that he just put down to ‘getting old’.

Further investigation revealed it was Stage 4 melanoma with the cancer spreading to his liver.

“When I first got the news, the prognosis wasn’t good. I was up all hours of the night researching what treatments were available and actually came across this exact research trial,” David said.

“I’ve since had both doses of the immunotherapy and the tumour on the side of my head all but disappeared after two weeks. I was literally seeing the results before my own eyes.”

“Now I’m onto the second part of the treatment where I’m being admitted as an inpatient at FSH to receive my cell therapy – I’m a little apprehensive but hopeful the treatment all works.”

“For any other advanced melanoma patients looking for treatment options, I recommend doing your research to see what’s available. Don’t give up – anything’s possible.”

It’s hoped the cellular therapy may also be effective other cancers such as lung cancers.

The international trial was a collaboration between the Medical Oncology Clinical Trials Unit and FSH Bone Marrow Transplant Lab.

Photo: Patient David Braund (second from left) with Professor Adnan Khattak (right).



"I'm really grateful for the simple, healthy life I now lead thanks to Olorofim and for being able to live to see my son grow up"

Daniel, patient

Trial drug helps double lung transplant survivor Daniel

49-year-old Margaret River resident Daniel has lived with cystic fibrosis since birth and received two lung transplants.

Daniel also survived a life-threatening fungal infection thanks to treatment by FSH researchers with the novel antifungal drug, Olorofim.

After catching a virus in 2019, Daniel struggled to breathe and was thankful to receive his second lung transplant. Shortly after, however, he developed an untreatable fungal infection.

"I had several rounds of antifungals, but the particular infection I had was not treatable with those drugs and my lung function was deteriorating," Daniel said.

"It was a miracle I could access Olorofim through the FSH trial right when I needed it."

Photo: Daniel (left) with Dr Heath

FSH was the only Western Australian site to provide treatment with Olorofim in its now complete '032 Study'. The treatment was lifesaving for Daniel and four other patients with previously untreatable and multi-drug resistant (MDR)/extremely drug-resistant (XDR) invasive fungal infections (IFIs).

These patients had not responded to any available licensed antifungal therapies, but thanks to Olorofim access in the 032 Study at FSH, all patients remain well to date.

Dr Christopher Heath – Infectious Diseases Physician and Clinical Microbiologist at FSH – is now following on from the successful 032 Study as principal investigator of the new OASIS study. The study will investigate the efficacy of oral Olorofim for treating invasive aspergillosis, a common IFI, as an oral alternative to the currently used intravenous AmBome treatment therapy.

"As we saw in the 032 Study, Olorofim was a lifesaving treatment for patients suffering IFIs from drug resistant fungal infections, and we hope it will have the same efficacy treating invasive aspergillosis" he said.

"Until now, there have been poor patient outcomes for IFIs from drug resistant fungal infections, particularly for patients with severe immunodeficiencies, haematological malignancies and/or organ transplantation, where most patients have sadly died."

Dr Heath, together with co-investigator Dr Peter Boan, Head of Infectious Diseases Dr Moira Wilson, Infectious Diseases Research Nurse Michelle England, and the FSH Haematology Bone Marrow Transplant and Lung Transplant teams, is providing hope for an effective treatment for patients suffering IFIs due to these drug resistant fungal pathogens.

"As in Daniel's case, this treatment could be the difference between survival or not," Dr Heath said.

Daniel hopes Olorofim will become more widely available for other IFI sufferers to access.

"I'm really grateful for the simple, healthy life I now lead thanks to Olorofim and for being able to live to see my son grow up" Daniel said.



Collaboration

SMHS is committed to building a collaborative research ecosystem which attracts funding and achieves impact within and beyond its catchment.

Forging connections

Research alignment between hospitals and universities is crucial to advancing healthcare knowledge, improving patient care and fostering innovation.

Facility upgrades improving research outcomes

Upgrades at the Harry Perkins Institute of Medical Research (the Perkins) – based adjacent to the FSH campus – are aiding research outcomes.

The first upgrade in October 2024 saw the Perkins purchase eight hospital-grade, electronic height-adjustable, wheeled examination beds with patient safety rails. These are used in consulting rooms and replaced the previous fixed-height beds.

FSFHG Clinical Nurse Manager – Research, Rachel West, said it was a wonderful addition to the consulting rooms suites for researchers at FSH to use.

“This upgrade demonstrates the Perkins commitment to reducing the potential risk of injury to both patients and staff. We look forward to further initiatives and the benefits these will bring to all involved,” Rachel said.

The upgrade was made possible thanks to a dedicated working group established in 2023 comprised of representatives from SMHS, the Perkins and The University of Western Australia. The group reviewed ways to continuously improve service delivery in line with the [National Clinical Trials Governance Framework](#).

SMHS Director Research Melanie Wright led the collaborative working group on behalf of SMHS, ensuring the health service improve the safety and quality of the environment in which it provides services to clinical trial participants.

Photo: FSFHG Clinical Nurse Manager – Research, Rachel West, and Harry Perkins Institute of Medical Research Facilities Manager, Jonathan Gabriel.

Spotlight: collaboration in research

Improving the ICU post operative cardiac surgery patient journey

Cardiovascular disease remains a leading cause of death in Australia. Coupled with an ageing population, it has fuelled a continuing demand for interventions such as cardiac surgery to alleviate or prevent cardiovascular events.

Refinements in cardiopulmonary bypass techniques and intensive care management strategies of cardiac surgery patients have improved both mortality and morbidity rates. They have also made surgery a more available option to older patients with various co-morbidities.

Matching this high demand for cardiac surgery is a continuing demand for intensive care unit (ICU) beds and resources. This keeps efficient and cost-effective resource management at the forefront for maintaining a sustainable health care system.

This project aimed to:

- gain an understanding of current practice related to care of the post operative cardiac surgery patient within the FSH ICU
- develop a practice framework to facilitate timely transition for cardiac patients through their ICU recovery and enhance their patient experience.

Outcomes included an ICU cardiac surgery nursing care map, developed in collaboration with researchers from Curtin University and successfully implemented mid-year. Preliminary observations indicated an increase in early mobilisation practices.

This project was completed by FSH ICU nurse Melissa Bedford whilst undertaking a Master of Philosophy at Curtin University.

MoST-TAP trial a possible game-changer for rare cancer patients

Patients with uncommon and rare cancers may be able to join a clinical trial at FSH that has received ethics approval to trial new drugs that reactivate the body's anti-tumour immune response and kill cancer cells.

Two immunotherapy drugs will be offered to eligible patients with rare cancers in the multi-centre clinical trial lead by The George Institute in New South Wales, with FSH one of the collaborators.

The clinical trial, known as 'MoST-TAP', will provide patients with rare cancer access to new drugs that may improve their survival rates.

Dr Wei-Sen Lam, FSH Head of Service, Medical Oncology said he hopes these new drugs will improve outcomes for cancer patients.

"We have seen similar drugs improve survival in many rare cancer patients, and we hope to see patients with these cancers living longer with access to these drugs," Dr Lam said.

Dr Lam is also the Medical Lead Teletrials at the WA Country Health Service, a program delivering clinical trials closer to home. He said the FSH Medical Oncology Clinical Trials Unit is collaborating with the WA Regional Clinical Trial Coordinating Centre to identify suitable oncology trials for delivery in WA regional health sites to extend trial access to country patients.

*FSH Medical Oncology
Research Officer Trish Barrett
and Head of Service, Medical
Oncology Dr Wei-Sen Lam.*



Exercise supporting the recovery of people with severe mental illness

A comprehensive toolkit of practical exercise therapy resources could be key to addressing the alarming gap in life expectancy of people with severe mental illness.

The toolkit was developed by researchers at The University of Western Australia's Mental Health and Exercise Laboratory in collaboration with the Fremantle Hospital Mental Health Service Exercise Physiology team.

The toolkit provides mental health services with evidence-based guidelines to implement potentially life-saving effective exercise therapy programs for patients with severe mental illness.

Better understanding the perspectives and challenges faced by adults with severe mental illness who engage in exercise will enhance design and implementation of exercise programs to better support their mental health and recovery.







Culture

SMHS continued to develop a positive and inclusive research culture throughout 2024.

New Clinical Lead – Research

There was a change in medical leadership in SMHS research in 2024. SMHS Clinical Lead – Research, Professor Merrilee Needham, temporarily left SMHS to pursue other opportunities at university level. Merrilee had worked in this capacity since early project improvement work in 2016, and we thank her for her years of dedication, excellent research leadership, determination to improve the status quo and great success in improving SMHS research culture and capability.

Following an expression of interest process, SMHS was delighted to appoint A/Professor Abdul Ihdayhid as Clinical Lead in November 2024.

“I am delighted to introduce myself as the new Clinical Lead – Research at SMHS. As an interventional cardiologist and researcher, I am passionate about bridging the gap between innovation, research, and



A/Professor Abdul Ihdayhid

real-world clinical care.

In this role, I look forward to working with our talented researchers, clinicians, and partners to strengthen SMHS’s research culture, foster collaboration, and translate innovative ideas into meaningful outcomes for our patients.

I believe research should be accessible, impactful, and embedded into everyday clinical practice. Whether you’re an experienced investigator or new to research, I am keen to support and grow opportunities across the institution.”

The Nursing and Midwifery Research Unit

In 2024, the Nursing and Midwifery Research Unit (NaMRU) made significant strides in its commitment to foster a research culture, build research capacity, and promote career pathways for nurses and midwives across SMHS.

This included:

- 25 nurses and midwives leading research projects
- 21 staff undertaking master’s and PhD programs across seven universities
- six nurses receiving research grants, scholarships or fellowships
- a total of 20 publications (an increase of 54 per cent from 2023).

Collaborations with our university partners continued to flourish. The appointment of additional Honorary Nursing and Midwifery Research Consultants brought our total to 10. These experienced

academic researcher contributions have been invaluable in mentoring and guiding research initiatives aimed at improving patient outcomes through evidence-based practice and knowledge translation.

As part of the SMHS commitment to strengthening our ongoing organisational partnership with SingHealth, in March we were honoured to host a visiting delegation of SingHealth nurses. Delegates spent the week touring many of our clinical services and learning about the quality improvement, research and clinical trials undertaken within SMHS. This international collaboration is key to fostering joint sharing of ideas and promoting knowledge exchange.

Building research capability skills was officially formalised through the first-time inclusion of clinical research in the registered nurse to specialisation program. As part of a six-month appointment, successful candidate Annie Wu from the FSH Ambulatory Emergency Care Centre undertook research training activities and worked on developing a guideline for pain assessment in cognitively impaired older adult patients. The Midwifery Research Internship program also saw success, with candidates completing their internships and publishing their projects in various midwifery journals.

As clinical trials and clinical research numbers increased across SMHS, so too did the need to build our workforce to enable projects to be conducted in accordance with local, state, and national guidelines, policies, and procedures. A staffing increase of 27 per cent for the year is testament to the growing need for nurses

and midwives with research knowledge and skills to be promoted and supported as a career pathway.

As the year concluded, we bid farewell to Nurse Director – Research, Olivia Gallagher and the unit looks forward to welcoming a new director in 2025.

The Allied Health Research Unit

2024 was another successful year for Allied Health research across all sites in SMHS. Our Research Capacity and Culture survey demonstrated substantial improvement in SMHS Allied Health research capacity and culture compared to 2020 and 2022. Survey findings also informed our strategies for the next two years and were shared via the *2024 SMHS Allied Health Research Report*.

Some of the teams' achievements include the following:

- The appointment of Dr Pamela Chen as our third FSFHG Allied Health Postdoctoral Research Fellow in collaboration with Curtin University.
- Tailoring Research Evidence and Theory (TREAT) Journal Clubs were completed at FH, with fantastic feedback from staff involved.
- 76 scientific documents were published, bringing the total over the past four years to more than 340 papers.
- Four successful grant applications were submitted, including to the FHRI Fund.



*A/Professor Vin Cavalheri,
Allied Health Research
Director FSFHG*

Seventh annual SMHS Research Showcase

On Wednesday 13 November 2024, the SMHS Research Support and Development Unit (RSDU) hosted the seventh annual SMHS Research Showcase. The showcase is an opportunity for the SMHS community to come together and reflect on the excellent research work accomplished over the past year.

The 2024 theme was 'Technology & AI: the future of research'. Participants heard from three inspiring keynote speakers:

- Three successful applications were submitted to the Curtin University (Faculty of Health Sciences) Summer Scholarship.
- Two ongoing external fellowships for Dr Piers Truter (FHRI Fund/WA Department of Health) and Dr Lisa van der Lee (Raine Clinician Researcher Fellowship).
- Three research awards (two from the Hospital Research Foundation and another from Curtin University).
- Being a 2024 SMHS Excellence Awards category finalist in the categories of:
 - **Excellence in Strengthening Partnerships**, for the Allied Health Research Unit
 - **Moorditj Dookoorniny (Board/CE) Award** for FSFHG Allied Health Research Director A/Professor Vin Cavalheri.
- 19 new SMHS Allied Health-led projects approved in the Research Governance Service (RGS).
- Funding for 23 staff (via an initiative from the WA Chief Allied Health Office and support from SMHS Executive) for a total of 124 research days to undertake research-related activities.
- Participation as a site in 10 multicentre national clinical trials.

- **Dr Biyanka Jaltotage** – Transforming cardiology with AI: a promising future ahead
- **Professor Fiona Wood AO** – AI and the future of burn care
- **Professor Andrew Maiorana** – Healthy connections mobile medi kit.

A three-minute project competition saw five novice investigators – Sahil Gera, Edward Truong, Leone Oh, Parmida Ghorbanian and Mahalia McEvoy – front a panel of judges. Congratulations to three-minute project competition award winner Parmida Ghorbanian for her presentation. 'Artificial Intelligence segmentation of non-invasive eye scans for cardiovascular disease.'



Three-minute project competition winners

Researcher of the Year

The SMHS Excellence Awards celebrate and reward high achieving staff who exemplify the SMHS values of **Care, Integrity, Respect, Excellence and Teamwork** in their service each and every day.

The Researcher of the Year award is presented to a SMHS employee who demonstrates exceptional commitment to research, with significant potential, or actual improved, outcomes for patients or the community.

At an awards presentation in November, FSFHG Consultant Physician Infectious Diseases, Associate Professor Laurens Manning, was announced as SMHS Researcher of the Year.

Through his roles as an infectious disease physician and clinical researcher at FSH, The University of Western Australia and Honorary Fellow at Telethon Kids Institute, Associate Professor Laurens Manning's diverse research portfolio continually improves outcomes for patients both locally and globally.

His work includes design and implementation of clinical trials and studies into diabetic foot infections, large scale observational studies and trials of peri-prosthetic joint infections, observational and pharmacological studies in children with malaria, and severe infections for older patients.



*Associate Professor
Laurens Manning*

A generous and engaging collaborator, Associate Professor Manning's leadership of national and international collaborative research and outstanding publication output has helped push SMHS to the forefront of Australian infectious diseases research. With over 150 published papers and 2,500 plus citations, his research has directly translated into improvements in clinical practice, changes to guideline recommendations and advances in safety, efficiency and quality of care.

We also congratulate our other finalist, FSFHG Consultant Cardiology, Professor Girish Dwivedi.

Spotlight: research culture

Striving to improve cardiac catheterisation protocols

Cardiac catheterisation is used to identify and treat narrow or blocked coronary vessels. Dye is injected via a catheter so the coronary can be seen on an angiogram scan. Blocked vessels may then require a balloon or stent to open them via a procedure known as percutaneous coronary intervention (PCI).

Catheterisation is mostly performed via the radial artery in the wrist. Following catheter removal, a radial compression device such as the TR Band® is inflated to stop bleeding (haemostasis).

Nurse researchers sought to assess the safety and feasibility of an accelerated TR Band® deflation protocol in patients following angiogram or PCI compared to standard practice. The researchers were awarded funding from the Francis Jones Fund Nursing & Midwifery Research Development Grant.

A total of 144 patients who had an angiogram only and 61 patients who had a PCI were studied. Research

nurses collected data retrospectively from medical records and by telephone follow-up with participants one week after their procedure.

Results indicated that when compared with standard care, accelerated TR Band® deflation by nursing staff following angiogram significantly reduced deflation time and steps with no significant difference in bleeding rates. Patient comfort and satisfaction scores were similar between the two groups.

Increased bleeding was noted with accelerated deflation following PCI. Little difference was noted in other outcome measures for this group however the small sample size may have limited reliability of these results. Further analysis is being conducted.



Narelle Read, Mandeep Singh and Carrie Janerka



Data

Empowering researchers and clinicians through the provision of accessible and available data is a priority for SMHS.

Research activity overview

At 31 December 2024, SMHS had **865** active research projects listed in the Research Governance Service (RGS) system.

Tables 1 and 2 provide an overview of research approval activity in SMHS from 1 January to 31 December 2024.

Table 1: SMHS HREC project approvals 2024

88	16	3
SMHS HREC approved	waivers of consent granted	GAA pathway granted (incapacitated patients)

*Note: projects may have approval from other approved ethics committees; therefore, not all projects need SMHS HREC approval

Monitoring: the Ethics team processed **893** project amendments in 2024.

Table 2: SMHS site authorisation (governance) approvals

Activity	Number of projects
Site authorisation approved – total by project	174
Site authorisation approved – total by health site	
Fiona Stanley Hospital	163
Fremantle Hospital	17
Rockingham General Hospital	12
Murray District Hospital	1
Community Physiotherapy Service	1
Mandurah Community Health Centre	0
Cockburn Health	1
Peel Health Campus	1
SMHS Executive	2
Total number of approvals	198
Project reviews in progress by Governance team at year end	57
Monitoring: the Governance team processed 1,773 project amendments	

Notes: One project can be conducted across multiple health sites, therefore the ‘approved by project’ data will not always equal the total number of approvals i.e. one project can be approved but include FSH, FH and RGH as sites, therefore three sites need to be approved.

Table 3 provides a comparison of ethics and governance (site authorisation) activity, as well as publications sourced from 2017 to 2024.

Table 3: Comparative data 2017–24

Descriptor	2017	2018	2019	2020	2021	2022	2023	2024
Ethics approvals	92	79	79	88	75	72	58	88
SMHS HREC waiver of consent	30	10	12	14	6	13	18	16
Site authorisation approvals	155	152	161	183	141	139	132	174
Publications	357	452	479	534	586	581	604	1,324*

*The librarians added a search across Web of Science in addition to PubMed this year, resulting in a higher volume of publications found. Due to the volume, the list of publications has not been included in this report.

Spotlight: data in research

SMHS Biobank

Launched in November 2022 as part of the *SMHS Strategic Plan 2021–2025*, the SMHS Biobank has expanded its reach and in 2024 collaborated with 11 research projects across FSH, strengthening research and innovation.

Initiatives in 2024:

- Staff permanency achieved.
- SMHS Biobank Governance Committee established.
- The procurement process for DNA extraction equipment began in August 2024.
- A second SMHS Biobank freezer was purchased and installed in December 2024, using grant funding from the [FHRI Fund – Research Infrastructure Support 2024](#).
- Negotiations with SMHS Legal continued to draft agreements for outside entities to access SMHS Biobank facilities.
- To support local business, SMHS Biobank labels were sourced from a local WA supplier rather than the former US-based supplier.

Table 4: SMHS Biobank customers 2024

Study status	RGS number	Project name	Project PI	Department	Type of samples collected
Recruitment Active	5948	VITA-AMP	Laurens Manning	Infectious Disease	Serum
Recruitment Completed	5415	A cross-sectional assessment of fatty liver in overweight and obese Western Australian Children	Oyekoya Ayonrinde	Hepatology	Serum
Recruitment Active	5413	Immune correlates of clinical outcomes in sarcoidosis	Girish Dwivedi	Cardiology	Serum, Plasma, Buffy Coat, Balf Cell, Balf Tissue, Urine
Recruitment Active	6186	The ROCIT-FMT Trial): a pilot phase I/II trial	Laurens Manning	Infectious Disease	Stool Swabs
Recruitment Active	6488	CASCADE-MI	Nick Lan	Cardiology	Serum, Plasma, Buffy Coat
Recruitment Active	6205	Cardiovascular Disease in patients with Diabetes-related Foot Ulcers	Emma Hamilton	Endocrinology	Serum
Recruitment Active	5278	POEMS	Edward Litton	Intensive Care	Stool Swabs
Recruitment Active	3289	Implement Study	Lydia Warburton	Oncology	Serum, Plasma, Buffy Coat
Completed		ANZNN Registry	Shail Mehta	Neonatology	Database Design
Yet to commence	5157	Investigation into the Pathophysiology of Delirium in Western Australia	Gideon Caplan	Geriatric	Paxgene RNA, EDTA
Yet to commence		PROSPECT Study	Helen Keen	Rheumatology	Serum, plasma, buffy coat

Scoping how cognitive impairment complicates emergency pain assessment and management

As people age, pain-causing conditions become an increasingly prominent reason for them to seek healthcare. Studies also show a significant proportion of people living with dementia, which is also on the rise, regularly suffer from some degree of pain.

Despite the availability of observational tools, there is no national clinical care standard for pain assessment of patients with cognitive impairment.

This nursing research audit sought to describe nurses' pain assessment practices for older patients with cognitive impairment presenting to the emergency department (ED). In collaboration with ED clinicians, an audit tool was developed and a validation exercise undertaken with three independent reviewers. Data was collected from patients over the age of 65 years admitted to the hospital during November 2023 with a recorded diagnosis of cognitive impairment.

The study concluded pain assessment of this patient cohort presenting for emergency care was not undertaken according to evidence-based best-practice. These results highlight the need for a clinical guideline on pain assessment of cognitively impaired older adults, directing staff to valid and reliable tools to assess pain for this cohort of patients.

This project was presented at the Australian Association Gerontology conference, with attendance funded by the Francis Jones Fund.

Faecal microbiota transplantation helping ICU patients

A pilot study at FSH is investigating the role that faecal microbiota transplantation (FMT) may play in providing lifesaving treatment for critically ill intensive care unit (ICU) patients.

Termed the 'ROCIT-FMT' trial, the study is investigating if FMT, supplied by Australian Red Cross Lifeblood, may help restore a healthy gut (digestive system) in ICU patients and improve their recovery and long-term outcomes.

FMT involves taking donated stool from a healthy voluntary donor, testing and processing it, before transferring it into the gut of a sick patient. The idea behind FMT is that you can transfer the donor's healthy gut flora to a patient and potentially restore a healthy balance of gut bacteria.

ROCIT-FMT trial investigator Dr Henco Nel said patients who require prolonged admission to the ICU are known to have a significant imbalance of good and bad gut bacteria.

"The human gut has millions of tiny living organisms and bacteria within it, and if there are too many of the wrong type of bacteria in our gut, it can contribute to severe illness," Henco said.

“This imbalance, known as dysbiosis, may become a driver of critical illness, contributing to prolonged ICU stay.

“Outcomes for ICU patients with persistent critical illness remain poor, and current therapies are largely supportive without addressing the underlying pathophysiology.”

Henco said the results of the trial are so far promising, and the trial is ongoing.

Currently in Australia, FMT is approved for the treatment of *Clostridioides difficile* infection, a condition involving overgrowth of bad bacteria in a person's gut. FMT is also under investigation as a potential therapeutic intervention for a broad range of conditions exhibiting dysbiosis.

Dr Henco Nel



ICU research study set to revolutionise care for critically ill patients

In a world first, a research study led by the FSH Intensive Care Unit (ICU) has the potential to transform critical care by identifying which patients carry multidrug resistant organisms as part of their gut microbiome and are at risk of developing associated infections whilst in ICU.

Due to increased antibiotic use, ICUs are high risk environments for acquiring and spreading multidrug resistant organisms – one of the highest global public health priorities identified by the World Health Organization.

The Prospective Observational Embedded Microbiome Study (POEMS) has leveraged usual ICU care practices to collect and store large scale samples from patients.

FSH ICU Consultant Professor Ed Litton said preliminary research suggests gut microbiome changes associated with ICU admission are profound and can drive the acquisition of multidrug resistant organisms and adverse outcomes including hospital acquired infection and increased risk of death.

“This is a world leading study – that for the first time – will give a picture of the gut microbiome of every patient in the ICU, both when they are admitted and again when they are discharged,” Ed said.



“It’s unique in embedding the acquisition of samples as part of the usual care provided by ICU clinicians so that every patient contributes, and again by linking these samples to the electronic medical record system so the findings can be put in context of the whole clinical picture.”

In less than two years, the POEMS has collected more than 6,200 samples, making it the largest ICU microbiome biobank in the world.

The McCusker Charitable Foundation provided a \$400,000 research grant to SMHS to help analyse the samples and generate new knowledge of how ICU gut microbiome changes influence outcomes, identify new targets for therapeutics, and target prevention of multidrug resistant colonisation and infection. The funding will also support two post graduate students to work on the study.

Hon. Malcolm McCusker AC KC and Tonya McCusker AM visited the FSH ICU to see firsthand where some of the most critically unwell patients are cared for.

“It was the first time we had toured FSH, and it was a great opportunity to hear from Ed, who is an extremely passionate researcher with an incredible knowledge of ICU practices,” Tonya said.

“We gained a better understanding of how this research study can not only benefit patients in Western Australia, but potentially change the way critically ill patients are treated across the globe.”

SMHS Director Research, Melanie Wright, said it was amazing to see the new SMHS Biobank supporting researchers and some of the sickest patients with this groundbreaking research, and thanked the McCusker Foundation for its generous support.

Photo: SMHS Director Research Melanie Wright, FSH ICU Consultant Professor Ed Litton, SMHS Chief Executive Paul Forden, Tonya McCusker AM and Hon Malcolm McCusker AC KC.



Support

SMHS is committed to providing its researchers with access to the infrastructure and 'can-do' support they need.

Research Support and Development Unit

Our RSDU continued to support all researchers within the SMHS community throughout 2024.

Its focus on education and collaboration within SMHS is vital to the organisation meeting the support pillar of change within the [SMHS Research Strategy 2023-2033](#).

RSDU highlights

- Now in its fourth year, there were twelve mentor/mentee matches in 2024 via our Research Mentoring Program, building on 22 matches in 2023, six in 2022 and four in 2021.
- More than 100 clinical trials are currently listed on the Clin Trial Refer App. An evaluation report completed by SMHS Director Research, Melanie Wright, secured a further three years' funding from the SMHS Research Steering Committee to continue marketing clinical trials using this app.
- 42 drop-in sessions were held in 2024, with 26 attendees in total.
- During March to October, seven education sessions were delivered to a total of 66 attendees.
- To celebrate International Women's Day (8 March 2024), 80 people registered for an event with presentations from:
 - **Emerita Professor Anne Williams**, Murdoch University School of Nursing, College of Health and Education
 - **Dr Dayse Tavora-Vieira**, FSFHG Head of Department, Audiology
 - **Dr Helen Dejong**, FSFHG Research Coordinator, Occupational Therapy.
- On International Clinical Trials Day (20 May 2024), RSDU staff manned the Community Booth in the FSH concourse to liaise with community and staff about clinical trials and promote the importance of the day. A news article was also circulated to thank clinical trials teams and trial participants.
- A morning tea was organised by SMHS Director Research Melanie Wright to acknowledge the efforts of staff on International Research Administrators Day (25 September 2024). The celebration was also lodged with the Australasian Research Management Society.



SMHS
RSDU Manager
Deborah Matthews

Research Business Support team

The Research Business Support team continued to provide valuable support to all researchers and research teams across SMHS. The team manages the financial and business tasks for all externally funded clinical trials, research grants and research fellowships.

In 2024, the team received a \$407,531 Research Infrastructure Support grant, funded by the FHRI Fund. The funds were allocated to improve resources, infrastructure, access to library articles, conference fees, staff salaries, licence fees and workshop/event fees.

SMHS Research Grants

The inaugural *SMHS Research Grants Strategy 2024–2026* was endorsed by the SMHS Research Steering Committee and published widely through SMHS communication channels. A Research Grants education session was also delivered to SMHS staff.

Table 5: Grant activity

Grant activity	2023	2024
Grants/ Fellowships submitted	34	53
Grant funding awarded	\$1,700,007	\$2,681,523
Letters of support	14	15

An example of grant success was the Fremantle Diabetes Study in [An evaluation of NHMRC funded Dementia and Diabetes research](#) (pg.43-44)

This report provides comprehensive insights into the research outputs, outcomes, and impacts of NHMRC-funded health and medical research in the areas of dementia and diabetes to support NHMRC’s mission of ‘building a healthy Australia.’

Research Integrity

SMHS Director Research Melanie Wright and Research Project Officer Isabella McGavock embarked on a project to better support researchers with research integrity and research conduct matters.

The Research Integrity Advisors (RIA) program was created and launched in 2024 by the Hon Stephen Dawson, MLC. After a competitive selection process, [nine inaugural SMHS RIAs were appointed](#), each serving a three-year term.

To support these advisors, a procedure manual and reporting app were developed and an alumni event held at the end of the year.

Improving access to publication funding support

In 2024, a further \$25,000 was committed to the Open Access Publication Fund to support the publication of research in open access journals.

Created in 2021, the fund supports researchers who conduct research at a SMHS site but do not have access to publication funding support. These may be novice researchers or those conducting investigator-led research with no publication support from universities or a grant.

The following publication received part funding.

Table 6: Publication part funded by SMHS in 2024

Researcher: Dr Ed Raby
Project title: Randomised Controlled Trial of Celecoxib for Acute Burn Inflammation and Fever
Journal title: Burns Open
RGS number: RGS731
Funding: \$2330

SMHS Human Research Ethics Committee (HREC)

The SMHS HREC is a national certified lead HREC (EC00265).

In 2024, the SMHS HREC held 11 monthly meetings, reviewing an average of six projects per meeting, plus one to two protocol modifications via substantial amendments. This includes requests for Waiver of Consent (projects minimal/no risk based on nine NHMRC criteria) and requests where subjects are unable to personally give consent. The *Guardianship Administration Amendment Act 2020* defines how consent can be obtained in this circumstance.

Each committee meeting must have at least one representative from the community, professional care, pastoral care, a lawyer, and those with research experience. These are drawn from a pool of 34 members who participate in two to three meetings each per year.

The Department of Health (DoH) commenced the transition to a central HREC model in 2024. This means that SMHS HREC now only sees low-risk applications and those requiring national approval (under National Mutual Acceptance), until the new DoH model is granted national certification. The SMHS HREC is due to close its operations mid-2025.

The committee's activities support the five pillars of the [SMHS Research Strategy 2023–2033](#).

- **Community** – input and perspectives are provided by volunteer community HREC Committee members.

- **Collaboration** – working in partnership with universities, research centres and DoH.

- **Culture** – ensuring public safety whilst encouraging and supporting quality research.

- **Data** – medical records and databases provide a fertile opportunity for research, and the committee assesses appropriate data access and management is conducted within legislation and policy.

- **Support** – provided by SMHS Ethics Coordinator Jeannette Pether and SMHS Ethics Administration Officer Beate Ferbert-Booth who are keen to see research proposals in advance to assist streamlining them through the ethics processes.

The SMHS HREC is also involved in assessing Authorised Prescriber status to medical practitioners as per the Therapeutic Goods Administration (TGA) processes.

All this work is only possible with the SMHS Ethics team, committee members and Deputy Chair Dr Ed Raby, to whom I am very grateful.

Emeritus Professor David Fletcher AM, MBBS, MD, FRACS, GAICD
Chair SMHS Human Research Ethics Committee



Emeritus Professor David Fletcher

Waiver of consent

The NHMRC highlights in the [National Statement on Ethical Conduct in Human Research 2023](#) that, depending upon the circumstances of an individual project, it may be justifiable to employ a waiver of the requirement for consent rather than seeking explicit consent.

To apply for a waiver of consent investigators must respond to Section 2.3.10 (a-i) of the National Statement highlighting the need for a waiver as well as an analysis of the associated risks and benefits of the project.

A waiver of consent can only be granted for low-risk projects which pose no more than the risk of discomfort to participants; this does not include any novel interventional research.

Table 7: Waiver of consent projects granted by SMHS HREC in 2024

RGS number	Project title
6530	Non operative versus operative management of hip fractures in Australia and New Zealand
6389	Antiviral refractory or resistant cytomegalovirus infection in Australasia
5448	A WA cancer registry-based study investigating impacts of Indigenous Status, location, gender, and socio-economic factors on bladder cancer outcomes
6237	The development and initial evaluation of a proactive model for early detection and management of clinical deterioration – ALERT
6441	Examining Respiratory Syncytial Virus Testing and Detections and the Clinical Phenotype of Adults Admitted to Hospital
6548	Evaluating the role of statins in breast cancer prognosis and management
6634	Partnering with patients and carers from Culturally and Linguistically Diverse (CALD) backgrounds to enable patient and carer activated escalation of care (Pcae) for clinical deterioration in an adult hospital setting`
6613	OPERATE: Older Persons Early Recognition, Access and Treatment in Emergencies - SMHS Intervention Evaluation
6190	Audit of Cardiac Computed Tomography and Computational Modelling to Predict Complications and Outcomes post Transcatheter Aortic Valve Replacement: ARREST-TAVR Registry
5932	Applications of Artificial Intelligence in Post-ablation Outcome Prediction in Patients with Atrial Fibrillation
6235	Clinical Audit on the State-Wide Management of Intracerebral Haemorrhages
6015	Neoadjuvant chemotherapy compared to upfront surgery for borderline-resectable pancreatic adenocarcinoma: Exploring the real-world experience in Western Australia

6900	The safety of short-term dialysis catheter positioning within the right heart and great thoracic vessels. A mixed methods study.
7053	Cardiovascular risk factors, morbidity and mortality in patients attending the multidisciplinary diabetes-related foot ulcer clinic
5977	Repercussions of the COVID-19 Pandemic on Surgical Patient Population in Western Australia: Associations with Post-Surgery Complications, in the Context of Modifiable Lifestyle Risk Factors
6976	HAPPEN: Holistic Antibody Prognosis and Prediction Evaluation Network

Table 8: Research involving incapacitated patients (GAA pathway) granted by SMHS HREC in 2024

RGS number	Project title
5157	Investigation into the Pathophysiology of Delirium in Western Australia
6186	Restoration of gut microbiota in persistent critical illness using faecal microbiota transplantation (The ROCIT-FMT Trial): a pilot phase I/II trial
6734	An implementation-effectiveness trial investigating feasibility, safety and efficacy of Best pRacticE guideline cAre physioTHERapy with addition of protocolised ventilator hyperinflation on patient-important outcomes for critically ill adults intUbated and ventilated with Pneumonia. (BREATHE UP)

Research Screener

The Research Screener web application applies machine learning techniques to semi-automate the research article screening process. Users can upload research abstracts from existing databases and manually screen a small portion of these articles. The application then actively learns the most relevant abstracts for the study and present these to the researcher during the screening process. This semi-automated approach can allow for thousands to tens of thousands of articles to be screened in hours and days rather than months.

To support our researchers, SMHS Director Research Melanie Wright conducted an evaluation report and secured a further three years funding from the SMHS Research Steering Committee to 2027.

Nine SMHS staff used a licence in 2024.

A/Professor Vin Cavalheri, FSFHG Allied Health Research Director manages licence applications with great assistance from SMHS and EMHS librarians.

Table 9: Project list: Research Screener

Staff	Profession/area	Project(s)
Merin Paul	Social Work	Scoping review on “elder abuse: challenges faced by social workers in identifying, responding to and intervening in a hospital setting
Emily Brogan	Speech Pathology	Scoping review of free flap reconstructions in head and neck cancer patients
Regan Preston	Clinical Nurse Consultant, Emergency Department	Literature review on hepatitis C and mental health
Nadine Radin	SMHS Health Promotion	Literature Review on modifiable lifestyle risk factors in general surgery patients during the COVID-19 pandemic
Adarsh Das	Trainee Registrar, Clinical Services (Palliative Care)	Systematic review on management of Intractable hiccups in a palliative care setting
Duncan Wright	Nursing and Midwifery Research	Literature review on main health concerns in males
Owen Taylor-Williams	Resident Medical Officer, Surgery	Literature review on bone mineral density in adults with Rheumatoid Arthritis
Guy Stanley	Medical Registrar	Literature review to investigate the time to computerised tomography metric
Pamela Chen	Senior Podiatrist	Literature review on diabetes-related foot disease

Research projects

Research projects listed in this report were collated by reviewing the WA Health online RGS reports, SMHS South Health Information Management System (SHIMS) database and SMHS Monthly Research approval reports to identify new projects approved to commence in the 2024 calendar year i.e. only those that had received site authorisation (governance) were included.

Table 10 details **174** research projects approved to commence at a SMHS site during 2024.

Table 10: Projects approved to proceed at a SMHS site in 2024

RGS number	Project title
426	Associations of PNEUmonia with Myocardial fibrOsis and Heart Failure (PNEUMO-HF)
821	Development of the integrated immuno-flowFISH method for application to multiple myeloma- FOR RGH SITE ADDITION ONLY
1504	Helping new mothers to breastfeed - before their babies are even born
1896	Clinical implementation of personalised medicine for WA cancers - FOR RGH SITE ADDITION ONLY
1968	Assessment of breast density as a potential surrogate for efficacy of adjuvant endocrine therapy in early breast cancer
1985	Prognostic and predictive significance of NOTCH induced transcription factors (NTFs) in stage III colon cancer
3000	The Metformin Aneurysm Trial (MAT)
3018	Clinical and cost effectiveness of a Fast Track Giant Cell Arteritis (GCA) Clinic in Western Australia compared with standard management of patients clinically suspected to have GCA
3802	Factors affecting ossiculoplasty hearing outcomes
3956	Exercise medicine as chemotherapy adjunct: a multi-component program in pancreatic cancer patients receiving neoadjuvant therapy
4131	Australian and New Zealand ED Airway Registry
4178	Study of Tofacitinib for treatment of chronic pouchitis (STOPit)
4839	Muscle growth and anabolism in intensive care survivors
5059	A multicentre, open-label randomised controlled trial of disease-modifying anti-rheumatic drug (DMARD) dose maintenance (USUAL CARE) vs DMARD discontinuation after reduction (STOP) in adult patients with rheumatoid arthritis and psoriatic arthritis on stable biologic or targeted synthetic (b/ts) DMARD therapy +/- conventional synthetic (cs)DMARD/s, who are in sustained low disease activity at baseline for cost-utility comparison and multiomic mechanistic analyses to predict success of down-titration strategies
5157	Investigation into the Pathophysiology of Delirium in Western Australia

5289	A brief intervention to aid smoking cessation: a randomized controlled trial in Intensive Care patients
5387	The KidGen National Kidney Genomics Program - improving diagnostic outcomes for Australian families with genetic kidney disease
5448	A WA cancer registry based study investigating impacts of Indigenous Status, location, gender, and socio-economic factors on bladder cancer outcomes
5496	The National Australian HCV Point-of-Care Testing Program: An observational cohort study to evaluate the use of finger-stick point-of-care hepatitis C testing to enhance diagnosis and treatment of HCV infection
5509	Invasive non-Aspergillus mould (NAM) infections: a multi-centre observational study
5519	A randomised controlled trial of Standard Of Care versus RadioAblation in Early Stage HepatoCellular Carcinoma
5536	National Palliative Care in Prisons (PiP) Project: a Gap Analysis of the provision of palliative care for people in Australian prisons
5538	The feasibility and preliminary effectiveness of exercise therapy in transdiagnostic mental health services
5554	Analysis of clinical outcomes following orbital fractures with associated retrobulbar haemorrhage secondary to facial trauma
5560	Evaluating the Hospital Discharge Planning Process for Adults with Newly Acquired Disability and Complex Support Needs: Barriers, Challenges and Facilitators of Timely and Effective Discharge
5610	A longitudinal, retrospective, multi-centre observational study to evaluate effectiveness, persistence, treatment patterns & safety of Australian patients receiving Early Access tofacitinib
5648	Infection outcomes in patients with haematological malignancies treated with novel therapies: a national, multi-site, Australian Study
5687	Hearing Registry: Objective and Subjective Hearing Outcomes in Hearing Implant Recipients in WA
5703	Can lung ultrasound predict post-operative pulmonary complications in high-risk post-operative cardiac surgery patients?
5734	An ALLG Phase II Study of CHOP and Tislelizumab in Elderly Patients with Hodgkin Lymphoma
5827	AUS-NET study. Implementing a Nurse-Enabled, Shared-Care Model to Address Unmet Needs of People with Neuroendocrine Tumours
5851	Comparing Quantra Hemostasis Analyzer to standard coagulation testing in Cardiac Surgery
5862	A multi-centre, early feasibility study evaluating the safety and functionality of the ORM-P2 system for differentiating tissue types in the resection bed during breast-conserving surgery
5887	The C*STEROID Trial. Antenatal corticosteroids prior to planned caesarean section delivery from 35+0 to 39+6 weeks gestation; a randomised controlled trial assessing the effects on neonatal respiratory morbidity and glycaemic control

5915	Factors influencing vertical transmission of protective antibodies of COVID-19 in Western Australian women and infants
5920	AMPLE-4: Topical Antibiotic Prophylaxis for Infections of Indwelling Pleural Catheters in Patients with Malignant Pleural Effusions
5921	Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease: a randomised controlled trial - DISCUS-IBD
5932	Applications of Artificial Intelligence in Post-ablation Outcome Prediction in Patients with Atrial Fibrillation
5964	The Australian and New Zealand Thoracic Clinical Quality Registry (ANZTHOR)
5977	Repercussions of the COVID-19 Pandemic on Surgical Patient Population in Western Australia: Associations with Post-Surgery Complications, in the Context of Modifiable Lifestyle Risk Factors
6004	Measurement of interface pressures imparted by different compression interventions
6013	Comprehensive Screening for Airway, Laryngeal and Pulmonary Outcomes Following Smoke Inhalation Injury:A Prospective Cohort, Hybrid Investigation-Implementation Study
6015	Neoadjuvant chemotherapy compared to upfront surgery for borderline-resectable pancreatic adenocarcinoma: Exploring the real-world experience in Western Australia
6025	The Right Treatment for the Right Person at the Right Time. Driving High-Value Aphasia Care through Meaningful Health System Monitoring
6035	CA0891043: A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance versus Lenalidomide Maintenance Therapy Alone in Adult Participants with Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMA-9)
6051	TOP-FLOR: Treatment Of newly-diagnosed Follicular Lymphoma with CELMoD BMS-986369, Rituximab +/- Nivolumab: An umbrella Bayesian Optimal Phase II study
6064	Survey of end-user opinion on the functionality of an e-Health clinical management system for children with inflammatory bowel disease in Australia
6104	Comparing Standard of Care Versus Apixaban in patients with a Ventricular Assist Device: a Parallel, randomised, non-inferiority, open label, control, pilot study, The Apixi-VAD trial
6143	Fasting mimicking diet and exercise medicine as adjuvant therapies in the treatment of patients with breast cancer (the FASTEX trial): a non-randomised controlled preliminary efficacy trial
6146	A Long-Term Extension, Multi-Center Safety Study of AV-101 in Subjects With Pulmonary Arterial Hypertension (PAH) Who Have Completed Study AV-101-002
6170	Predicting AAA progression: Biomechanics meets Phenomics: Towards understanding and predicting abdominal aortic aneurysm (AAA) disease progression
6186	Restoration of gut microbiota in persistent critical illness using faecal microbiota transplantation (The ROCIT-FMT Trial): a pilot phase I/II trial

6190	Audit of Cardiac Computed Tomography and Computational Modelling to Predict Complications and Outcomes post Transcatheter Aortic Valve Replacement: ARREST-TAVR Registry
6205	The prevalence and pathophysiology of asymptomatic Cardiovascular Disease in patients with Diabetes-related Foot Ulcers and its impact on ulcer healing
6218	Real-world multicentre study of efficacy and safety of Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma (HCC)
6223	Decompression Illness Registry
6235	Clinical Audit on the State-Wide Management of Intracerebral Haemorrhages
6237	The development and initial evaluation of a proactive model for early detection and management of clinical deterioration – ALERT
6259	A Phase II, Multicenter, Double Blinded, Randomized, Placebo Controlled, Parallel-Group, Single-Dose Study to Determine the Safety, Preliminary Efficacy, and Pharmacokinetics of ARG007 in Acute Ischemic Stroke Patients
6261	A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis
6262	Audit of intravenous fluid boluses during induction of labour
6273	The SCIP Syphilis Project: Clinician Perspectives
6279	Defining clinically meaningful PFS improvement for men with metastatic prostate cancer
6282	Human microbial-immune priming in early life: Implications in pre-term infections (IMPriNts study)
6288	The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study
6289	The Australia and New Zealand Targeted Axillary Dissection Registry
6291	Towards Quality indicators for endoscopic surveillance for dysplasia surveillance in patients with IBD (TORQUE)
6298	Clinical Impressions of Prognosis and Interventions by West Australian critical care providers
6299	Development of artificial intelligence-guided cardiac auscultation to improve diagnosis of valvular heart disease
6302	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH) and Fibrosis
6303	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Nonalcoholic Fatty Liver Disease (NAFLD)
6304	eQUIT: A randomised controlled trial of electronic resources to help smokers undergoing lung cancer screening quit
6315	Establishing hypothetical antibiotic prescribing thresholds for hospital-onset VRE incidence and infection in Australian hospitals

6322	A Phase 2/3, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Subjects with Moderately to Severely Active Ulcerative Colitis with an Inadequate Response to Conventional Therapy
6325	Benchmarking respiratory physiotherapy practice for ICU patients with inhalation burn injury across Australia and New Zealand
6327	ATA3219-NHL-103: A Phase 1 Study to Evaluate the Safety and Preliminary Efficacy of ATA3219, Allogeneic Anti-CD19 Chimeric Antigen Receptor T-cell Therapy, in Subjects with Relapsed/Refractory B-cell non-Hodgkin Lymphoma
6339	MAGNITUDE: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)
6356	A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma
6365	Evaluation of a game-based learning simulation to enhance pandemic preparedness for nursing staff in Western Australia
6368	Determination of bone mineral density from a hand radiograph: Facilitating early identification of osteoporosis
6369	BESTOW: A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Tegoprobart in Patients Undergoing Kidney Transplantation
6377	A randomized, double-blind, placebo-controlled, parallel group, Phase 3 study, followed by open-label extensions, to evaluate the efficacy of oral belumosudil in adult participants with chronic lung allograft dysfunction (CLAD) following bilateral lung transplantation
6385	FARADISE: Real world Data collection in subjects treated with the FARAPULSE™ Pulsed Field Ablation system
6389	Antiviral refractory or resistant cytomegalovirus infection in Australasia
6390	A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegast) for the treatment of idiopathic pulmonary fibrosis
6391	Heart Failure Registry
6397	A phase 2b, multinational, randomized, double-blind study to investigate the efficacy and safety of redasemtide (S-005151) compared with placebo in adult participants with acute ischemic stroke who are not eligible for tissue plasminogen activator or thrombectomy
6399	EFC17757: A randomized, double-blind, multicenter, Phase 3 study to evaluate efficacy and safety of belumosudil in combination with corticosteroids versus placebo in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease (cGVHD) (ROCKnrol-1)
6400	BGB-11417-301: A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia

6402	A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
6410	Wait a Minute or More: A pragmatic stepped wedge cluster randomised implementation trial
6412	DeLLphi-306: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) who Have not Progressed Following Concurrent Chemoradiation Therapy
6420	An observational study of Cxbladder performance for the detection of urothelial carcinoma in patients presenting with haematuria
6424	M22-003: A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)
6427	The Role of FAPI-46 PET Imaging in Predicting Prognosis and Response to Immunotherapy in Metastatic Cancers
6431	Implementation of buddy taping as routine management for boxer's fractures: The impact on the health service and patients
6441	Examining Respiratory Syncytial Virus Testing and Detections and the Clinical Phenotype of Adults Admitted to Hospital
6447	Management of moderate POstoperative recurrence in Crohn's disease: a randoMizEd contROlled trial of therapeutic escalation, the POMEROL trial.
6450	The effects of hypoxia on cardiac function during endurance and sprint cycling
6452	ARTEMIDE-Biliary01: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent
6458	The effectiveness of indocyanine green in ureteric identification in Gynaecological Surgery
6483	A study on geographic variations in appendectomy outcomes within Western Australia assessing the impact of surgical wait times and rate of negative appendectomies in both urban and rural locations statewide
6484	Can Molecular Testing in Early Stage Non-Small Cell Lung Cancer Identify Patients at Risk of Recurrence Post Resection?
6488	Coronary Artery disease SCreening in young ADult relativEs of individuals with premature Myocardial Infarction
6496	An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER™-ON)
6498	Advancing Evidence Based Care After Breast Cancer Radiation Treatment: A Multimodal Imaging Approach to Quantify Inflammation and Fibrosis
6507	MoST-TAP. A single arm, open-label, phase II signal-seeking trial of tiragolumab and atezolizumab in patients with advanced solid tumours
6522	Building Antifragility in Supply Chain Management: How Can Technologies of Industry 4.0 Help?

6523	CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degradar) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
6524	The patient and hospital staff experience of an emergency department musculoskeletal diversion pathway: a qualitative study
6525	A consumer lens on future research and innovation in care provision for patients with injuries: A world cafe approach
6530	Non operative versus operative management of hip fractures in Australia and New Zealand
6545	Virtual Reality intervention for burns dressing changes; efficacy, implementability and predictors of success
6548	Evaluating the role of statins in breast cancer prognosis and management
6549	What factors help or hinder midwives' implementation of evidence-based practice in one tertiary maternity service in Western Australia?
6551	Assessing outcomes of Janus Kinase Inhibitor use for the management of Acute Severe Ulcerative Colitis: SAVE-IT
6555	Amino Acid Infusion for Renal Protection in Lutetium-177 PSMA I&T Therapy for Metastatic Prostate Cancer: A Study on Renal Dosimetry Using 3D SPECT/CT Imaging
6557	A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study with Single Blind Sentinel period to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IGNX001 in Peanut-Allergic Adults and Older Adolescents
6566	A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in Non-Cirrhotic Subjects with Nonalcoholic Steatohepatitis (NASH)
6587	Medial Patellofemoral Ligament Reconstruction: A Retrospective Case Series (MPFL Study)
6590	Safety, tolerability and pharmacokinetics of 2g subcutaneous ceftriaxone as an alternative to intravenous administration
6613	OPERATE: Older Persons Early Recognition, Access and Treatment in Emergencies - SMHS Intervention Evaluation
6623	STELLAR 305. A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY OF ZANZALINTINIB (XL092) IN COMBINATION WITH PEMBROLIZUMAB VS PEMBROLIZUMAB IN THE FIRST-LINE TREATMENT OF SUBJECTS WITH PD-L1 POSITIVE RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
6626	The Chronic kidney disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect (CAPTIVATE)

6634	Partnering with patients and carers from Culturally and Linguistically Diverse (CALD) backgrounds to enable patient and carer activated escalation of care (PCAE) for clinical deterioration in an adult hospital setting`
6659	Effects of NNC0194-0499 alone and in combination with semaglutide, of semaglutide alone, and of cagrilintide alone and in combination with semaglutide on liver damage and alcohol use in people with alcohol-related liver disease
6660	Pragmatic trial of lifestyle modifications reducing pregnancy Group B Streptococcus colonisation in pregnancy- A Midwifery Led Initiative
6679	TroFuse-019: A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery
6682	The efficacy and safety of combination biologics and immunomodulator therapies in inflammatory diseases: A retrospective study
6688	TRIUMPH-OUTCOMES: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants with Body Mass Index ≥ 27 kg/m ² and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
6690	TroFuse-010: An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician's Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer
6692	A Long-Term Follow-up Study for Subjects with Chronic Hepatitis B Previously Treated with Imdusiran (AB-729)
6731	OLIO: A phase II, randomised, non-comparative two-arm trial of neoadjuvant chemotherapy plus either olaparib or olaparib + durvalumab in young, pre-menopausal women with HRD-enriched, HR-positive, HER2-negative early breast cancer
6734	An implementation-effectiveness trial investigating feasibility, safety and efficacy of Best pRacticE guideline cAre physioTHERapy with addition of protocolised ventilator hyperinflation on patient-important outcomes for critically ill adults intUbated and ventilated with Pneumonia. (BREATHE UP)
6746	A randomised, double blind placebo-controlled trial evaluating the medical food synbiotic SBD121, versus placebo for the clinical dietary management of early Rheumatoid Arthritis
6765	An Observational Multi-center Study to Evaluate Real-World Treatment Outcomes of Durvalumab-based Regimens in Hepatobiliary Cancers
6766	BALANCE+: A platform trial for gram-negative bloodstream infections
6770	Barriers and enablers for delivery of teleprehabilitation education in the lung and abdominal cancer surgery population: A mixed methods case study
6774	Driving chronic wound repair using CANN001, a hydrogel patch containing 2-deoxy-D-Ribose; a safety trial
6779	Immune Effector Cell Profiling in Non-Hodgkin Lymphoma

6780	Exploring the Impact of Patient Suicide on Mental Health Clinicians' Wellbeing
6782	A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
6784	A Multicentre, Phase 1 Study Investigating the Safety, Tumour Uptake, Biodistribution, and Dosimetry of 68Ga-A9T-3202 in Participants with Locally Advanced or Metastatic Melanoma
6789	REVIVE: REspiratory syncytial Virus Immunisation program - eValuating Effectiveness and impact
6804	Clarity-PT01: A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing Claudin 18.2
6815	Midwife-led debriefing intervention: An implementation science project using a validated counselling tool for perinatal post-traumatic growth
6823	BALANCED -HF study A Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared to Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function
6828	An evaluation of early intervention using compression garments following neck dissection surgery for head and neck cancer and the impact on lymphoedema
6844	Person-centred Care Starts at Emergency Department Triage
6845	Comparison of an accelerated deflation protocol with standard practice for radial compression device following cardiac catheterisation
6869	Investigation of the impact of timing of acute surgery on longitudinal post-burn outcomes
6874	A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study with an Open-Label Extension to Investigate the Efficacy and Safety of Solrikutug in Adults with Eosinophilic Esophagitis (ALAMERE)
6878	A Phase 2b / 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects with End Stage Kidney Disease Undergoing Dialysis
6884	Assessing the Impact of Cardiac Rehabilitation on Functional Status Post-Surgery. A DASI Score Analysis in Adult Cardiac Surgery Patients: A pilot study
6895	Positron Emission Tomography using 64Cu-SAR-bisPSMA in participants with high-risk prostate cancer prior to radical prostatectomy: A prospective, single-arm, multi-centre, blinded review, Phase 3 diagnostic performance study
6900	The safety of short-term dialysis catheter positioning within the right heart and great thoracic vessels. A mixed methods study.
6913	Exploring the similarities and differences in allied health professional training needs across the Australian Health system - a cross-sectional study

6914	Exploring the accuracy of hepatocellular carcinoma predictive models in MASLD: a retrospective cohort study
6930	Validation of a novel ultrasound vein finding device
6953	Mixed method analysis of Australian healthcare services current serious adverse event investigation practices
6976	HAPPEN: Holistic Antibody Prognosis and Prediction Evaluation Network
6977	AFICAMTEN (CK-3773274): A Phase 3, Multi-Center, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults with Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
6999	Pioneering innovative, sustainable and scalable solutions to improve the utilisation of pulmonary rehabilitation programs in Perth, Western Australia
7024	Appraising the utility of whole tumour heterogeneity assessment by novel HER2 PET scanning compared to standard-of-care FDG-PET scanning in metastatic breast cancer
7051	A Phase 3 Study to Evaluate the Efficacy and Safety of Pegzofermin in Subjects with Compensated Cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)
7053	Cardiovascular risk factors, morbidity and mortality in patients attending the multidisciplinary diabetes-related foot ulcer clinic
7071	A randomised study of cessation of somatostatin analogues after Peptide Receptor Radionuclide Therapy in Mid, Hind-Gut and Pancreatic Neuroendocrine tumours
7084	Assessing Work-related Wellbeing amongst Anaesthetic Consultants at Fiona Stanley Fremantle Hospitals Group (FSFHG): A Repeated Cross-Sectional Study
7106	SMHS nurses' and midwives' self-assessment of digital health capabilities: A cross-section study
7137	Long-Term follow-up of Study 32: an open-label single-arm Phase IIb study of F901318 as treatment of invasive fungal infections due to Lomentospora prolificans, Scedosporium spp., Aspergillus spp., and other resistant fungi in patients lacking suitable alternative treatment options (F901318/0032-LTFU)
7163	Designing and implementing novel health informatics approaches to improve outcomes for people with mild TBI across Australia (AUS-mTBI APP)
7188	The Chronic kidney disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect (CAPTIVATE) – Finerenone
7249	Effect of supplementary pasteurised donor human milk compared with infant formula on length of neonatal hospital stay, morbidity, breastfeeding, growth, development and health care costs in moderate and late preterm babies – a randomised controlled trial
7260	Improving pain assessment for patients with cognitive impairment in the emergency department

This document can be made available in alternative formats on request.

South Metropolitan Health Service

14 Barry Marshall Parade, Murdoch WA 6150

smhs.health.wa.gov.au

Compiled: Research Support and Development Unit, April 2025 v1.0

Publication number - 2025-SMHS-2386 20250623

© State of Western Australia, South Metropolitan Health Service, 2025